Key Points – Organigram Global posted weaker fiscal Q2 2026 results, with net revenue down about 9% year over year to CAD 59.8 million and adjusted EBITDA falling to CAD 0.9 million.
Management blamed operational issues in vapes and infused pre-rolls, softer Canadian market growth, and international flower spec challenges. – The company said it is taking corrective action, including tighter quality controls for infused pre-rolls and a product refresh in vapes, where share fell as consumer demand shifted toward higher-potency formats
Despite those setbacks, Organigram said flower, edibles, beverages and concentrates showed strength and it remained Canada’s No. 1 licensed producer by market share. – Organigram expects the recently completed Sanity Group acquisition to boost international growth, especially in Germany, and raised fiscal 2026 guidance to net revenue above CAD 350 million with adjusted EBITDA and adjusted gross margin above fiscal 2025 levels. The company also reported improved cash flow and said it still has around CAD 40 million of available liquidity after financing. – Three Reasons It’s Time To Get Bullish On Organigram Organigram Global (NASDAQ:OGI) reported a weaker second quarter for fiscal 2026, with management attributing the decline to operational issues in key product categories, softer Canadian cannabis market growth and continued challenges with international flower specifications. Chief Executive Officer James Yamanaka, who joined the company about four months ago, said the quarter was “challenging” but emphasized that Organigram has identified the issues affecting performance and is taking corrective steps.
He said the company remains focused on execution, improving underperforming areas and integrating the recently acquired Sanity Group beginning in the third quarter. – OrganiGram’s Turnaround Begins To Blossom Net revenue for the quarter was CAD 59.8 million, down from CAD 65.6 million in the prior-year period, a decline of about 9%….